AbbVie Inc. (NYSE:ABBV) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...
Leerink Partnrs Estimates AbbVie’s Q1 Earnings (NYSE:ABBV)
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...
AbbVie secures $3 billion credit facility, total access now $8 billion
AbbVie Inc . (NYSE:ABBV), a Delaware-incorporated pharmaceutical company with a market capitalization of $339 billion and annual revenue exceeding $56 billion, has entered into a $3 billion unsecured ...
Jim Cramer Says AbbVie Inc. (ABBV) Is A ‘Buy’
We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...
FiercePharma17h
TV drug ad spending reached new heights in January, as Novartis' Pluvicto toppled AbbVie's Skyrizi for top spot
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.